Fig. 5

RELB-P53 suppresses endothelial growth in the absence of PKM2. a EdU and phospho-Histone H3 positive cell numbers in control, RELB^KD, PKM2^KD and PKM2^KD/RELB^KD ECs (n = 6). b Western blot analysis of RELB, P53, P21 and PKM2 expression in control, RELB^KD, PKM2^KD and PKM2^KD/RELB^KD ECs. c EdU and phospho-Histone H3 positive cell numbers in control, P53^KD, PKM2^KD and PKM2^KD/P53^KD ECs (n = 12). d Western blot analysis of RELB, P53, P21 and PKM2 expression in control, P53^KD, PKM2^KD and PKM2^KD/P53^KD ECs. e mRNA expression levels of key enzymes for pyrimidine synthesis in control, P53^KD, PKM2^KD and PKM2^KD/P53^KD ECs (RNA-seq analysis, n = 3). f Relative N-carbamoyl aspartate levels, UTP levels, incorporation of [U-13C₆]-glucose into m+3 and m+5 UTP, and relative dTTP levels in control, P53^KD, PKM2^KD and PKM2^KD/P53^KD ECs (n = 3). a, c Data represent means ± s.e.m., e, f data represent means ± s.d., m+n represents the mass isotopomers for individual metabolites (***P < 0.001, **P < 0.01, *P < 0.05 by one-way analysis of variance (ANOVA) followed by Tukey’s HSD test)